DoseMe Partners with DaiKnow to Advance Model-Informed Precision Dosing in India
In this article:
DoseMeRx is critical to the nation’s clinicians and patients at a time when the discussion is pointing to vancomycin AUC value in outcomes
Jupiter, FL – March 18, 2025
DoseMe, a leader in model-informed precision dosing (MIPD), has announced a strategic partnership with DaiKnow to advance the adoption of MIPD in India. This collaboration comes at a pivotal moment as India’s scientific research continues to show the value of MIPD as part of day-to-day clinical practice to achieve precise, effective dosing.
India is at a critical juncture where precision dosing is gaining momentum in clinical practice, particularly in response to the increasing focus on vancomycin Area Under the Curve (AUC) monitoring to optimize patient outcomes. DoseMe and DaiKnow are working together to ensure clinicians have access to best-in-class tools and education to support this paradigm shift in patient care.
“Precision dosing has the potential to significantly improve patient care and enhance global health outcomes,” said Vinay Singh, Managing Director at DaiKnow. “ Through our partnership with DoseMe, we are committed to providing clinicians with the tools and knowledge they need to make data-driven dosing decisions, ensuring every patient receives the right dose at the right time.”
As India continues its journey toward integrating precision medicine into routine care, the timing of this partnership is ideal. The conversation around vancomycin AUC monitoring is gaining momentum, and clinicians are recognizing the need for precise, effective monitoring to guide treatment decisions.
“This partnership underscores the shared vision of DoseMe and DaiKnow in bridging the gap between scientific advancements and clinical implementation,” stated Paul Edwards, CEO of DoseMe. “By fostering education, engagement, and access to precision dosing technology, the collaboration aims to empower healthcare professionals in India and beyond to embrace model-informed dosing strategies for better patient outcomes.”
For more information, contact sales@dosemehealth.com
About DoseMe
DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories